

**MYASTHENIA GRAVIS: A COMPREHENSIVE REVIEW OF AN AUTOIMMUNE  
NEUROMUSCULAR DISORDER**

**Dr. K. Siva Rama Gandhi<sup>\*1</sup>, Dr. N. Suvarna Jyothi<sup>2</sup>, Yadla Jerusha Gold<sup>3</sup>, Gogannamatam Lalitha Sagar<sup>4</sup>,  
Vara Sravanthi<sup>5</sup>, Burra Ramyasri<sup>6</sup>**

<sup>1</sup>Neurologist, Apollo Hospitals, Kakinada, Andhra Pradesh, India.

<sup>2</sup>Principal & Professor, Koringa College of Pharmacy, Korangi, Kakinada, Andhra Pradesh, India.

<sup>3,4,5,6</sup>Pharm D Scholar, Department of Pharmacy Practice, Koringa College of Pharmacy, Korangi, Kakinada, Andhra Pradesh, India.



**\*Corresponding Author: Dr. K. Siva Rama Gandhi**

Neurologist, Apollo Hospitals, Kakinada, Andhra Pradesh, India.

DOI: <https://doi.org/10.5281/zenodo.18797709>

**How to cite this Article:** Dr. K. Siva Rama Gandhi<sup>\*1</sup>, Dr. N. Suvarna Jyothi<sup>2</sup>, Yadla Jerusha Gold<sup>3</sup>, Gogannamatam Lalitha Sagar<sup>4</sup>, Vara Sravanthi<sup>5</sup>, Burra Ramyasri<sup>6</sup> (2026). Myasthenia Gravis: A Comprehensive Review Of An Autoimmune Neuromuscular Disorder. World Journal of Pharmaceutical and Medical Research, 12(3), 99–104.

This work is licensed under Creative Commons Attribution 4.0 International license.



Article Received on 17/01/2026

Article Revised on 06/02/2026

Article Published on 01/03/2026

**ABSTRACT**


Myasthenia gravis (MG) is a chronic autoimmune disorder of the neuromuscular junction characterized by fluctuating skeletal muscle weakness and abnormal fatigability. The condition is primarily caused by autoantibodies directed against postsynaptic acetylcholine receptors, and less commonly against muscle-specific kinase or related proteins, leading to impaired neuromuscular transmission. Clinically, MG presents with variable involvement of ocular, bulbar, limb, and respiratory muscles, with symptoms typically worsening on exertion and improving with rest. Diagnosis is established through clinical evaluation supported by serological testing, electrophysiological studies, and imaging of the thymus. Management includes acetylcholinesterase inhibitors, immunosuppressive therapy, thymectomy, and immunomodulatory treatments such as plasmapheresis and intravenous immunoglobulin. Recent advances in targeted immunotherapies have further improved disease control and patient outcomes. This review provides a comprehensive overview of the etiology, pathophysiology, clinical features, diagnostic approaches, and current management strategies for myasthenia gravis, emphasizing the importance of early diagnosis and individualized treatment to enhance quality of life.

**KEYWORDS:** Myasthenia gravis; Autoimmune neuromuscular disorder; Acetylcholine receptor antibodies; Neuromuscular junction; Thymectomy; Immunosuppressive therapy; Acetylcholinesterase inhibitors.

**INTRODUCTION**

Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disorder characterized by fluctuating weakness and fatigability of voluntary muscles. The disease results from impaired neuromuscular transmission due to autoantibodies directed against key components of the postsynaptic membrane, most commonly the acetylcholine receptor. These immune-mediated processes reduce the availability of functional receptors, leading to compromised muscle contraction and strength. MG affects individuals across all age groups, with a bimodal distribution—frequently occurring in younger women and older men. Clinical presentation ranges from isolated ocular symptoms to generalized involvement of bulbar, limb, and respiratory

muscles, which may progress to life-threatening myasthenic crisis. Thymic abnormalities, including thymic hyperplasia and thymoma, are commonly associated. Advances in diagnostic methods and therapeutic strategies have significantly improved outcomes; however, myasthenia gravis remains a condition requiring long-term, individualized management. This review outlines current understanding of the etiology, pathophysiology, clinical manifestations, diagnosis, and management of MG.



## Myasthenia gravis

### Etiology

Myasthenia gravis is an autoimmune disorder resulting from immune-mediated disruption of neuromuscular transmission. Its etiology is multifactorial, involving immunological, genetic, and environmental influences.

### 1. Autoimmune Mechanisms

MG is characterized by the production of autoantibodies against postsynaptic neuromuscular junction proteins, leading to impaired transmission. The principal antibodies include.

- Acetylcholine receptor (AChR) antibodies
- Muscle-specific kinase (MuSK) antibodies
- Lipoprotein-related protein 4 (LRP4) antibodies

These antibodies cause receptor degradation, complement-mediated injury, and functional blockade.

### 2. Thymic Abnormalities

The thymus plays a central role in MG pathogenesis. Thymic hyperplasia is commonly observed in early-onset MG, while thymoma is associated with a subset of patients and contributes to loss of immune tolerance.

### 3. Genetic Predisposition

Certain HLA haplotypes increase susceptibility to MG. Genetic factors influence immune regulation and antibody production but do not directly determine inheritance.

### 4. Environmental and Triggering Factors

Infections, emotional stress, surgery, pregnancy, and specific medications may precipitate or exacerbate MG.

Drugs such as aminoglycosides, beta-blockers, and magnesium-containing agents can worsen symptoms.

### 5. Idiopathic Factors

In some patients, no identifiable antibodies or triggers are detected, a condition referred to as seronegative myasthenia gravis.

### Risk Factors

Myasthenia gravis (MG) is a multifactorial autoimmune disorder, and several risk factors have been identified that contribute to disease development and progression.

**1. Age and Sex Bimodal age distribution Early-onset MG:** more common in younger females **Late-onset MG:** more common in older males.

**2. Genetic Susceptibility** Presence of specific HLA haplotypes (e.g., HLA-B8, HLA-DR3) Family history of autoimmune diseases increases risk.

**3. Thymic Abnormalities:** Thymic hyperplasia Thymoma Structural or functional thymic abnormalities promote autoantibody production.


**4. Autoimmune Disorders:** Coexisting autoimmune diseases such as: Thyroid disorders Systemic lupus erythematosus Rheumatoid arthritis.

**5. Environmental and Triggering Factors Infections:** Physical or emotional stress Surgery or trauma Pregnancy and postpartum period.



**6. Drug-Related Factors:** Medications that may induce or exacerbate MG

symptoms: Aminoglycoside antibiotics Beta-blockers Calcium channel blockers Magnesium-containing drugs.

**7. Immune Dysregulation:** Altered immune tolerance leading to autoantibody production.



**Pathophysiology**



**Clinical Presentation**

Myasthenia gravis (MG) is characterized by fluctuating weakness of voluntary skeletal muscles, which typically worsens with activity and improves with rest. The

clinical manifestations vary depending on the muscle groups involved and disease severity.

1. Ocular Manifestations Ptosis (drooping of one or both eyelids) Diplopia (double vision) Extraocular muscle weakness Often the initial presentation in many patients.
2. Bulbar Muscle Involvement Dysarthria (slurred or nasal speech) Dysphagia (difficulty in swallowing) Difficulty chewing and facial weakness Fatigable jaw movements.
3. Limb and Axial Muscle Weakness Proximal muscle weakness (arms and legs) Difficulty in activities such as climbing stairs, lifting objects, or combing hair Neck flexor and extensor weakness (head drop).
4. Respiratory Muscle Involvement Dyspnea and reduced respiratory capacity Myasthenic crisis: acute respiratory failure requiring ventilatory support.
5. General Characteristics Muscle weakness worsens with repeated use Improvement after rest or with acetylcholinesterase inhibitors. Sensory function and reflexes are usually normal No muscle atrophy in early stages.
6. Disease Course Fluctuating and progressive in nature may remain ocular or progress to generalized MG within months to year.

### Diagnosis

The diagnosis of myasthenia gravis (MG) is primarily clinical, supported by laboratory, electrophysiological, and imaging investigations to confirm the disorder and guide management.

**1. Clinical Assessment:** Fluctuating, fatigable weakness of voluntary muscles Worsening with activity, improvement with rest Commonly affects ocular (ptosis, diplopia), bulbar (dysarthria, dysphagia), limb, and respiratory muscles Normal sensory function and reflexes Disease course may be ocular or generalized.

**2. Serological Tests:** Anti-acetylcholine receptor (AChR) antibodies – present in ~85% of generalized MG Anti-MuSK antibodies – in AChR-negative patients, often with bulbar involvement Anti-LRP4 antibodies – less common Seronegative MG – when all antibodies are absent.

**Electrophysiological Studies:** Repetitive nerve stimulation (RNS): shows decremental muscle response Single-fiber electromyography (SFEMG): increased jitter, most sensitive test for detecting impaired neuromuscular transmission.

**Pharmacological Tests:** Edrophonium (Tensilon) test or neostigmine test can temporarily improve muscle strength, but less commonly used due to safety concerns

**5. Imaging Studies:** CT or MRI of the chest: evaluates for thymic abnormalities (thymoma or thymic hyperplasia), which are associated with MG.

### Management

The management of myasthenia gravis (MG) is aimed at improving muscle strength, controlling symptoms, preventing complications, and addressing the underlying autoimmune pathology. Treatment is individualized

based on disease severity, antibody status, and patient comorbidities.

### Symptomatic Treatment

1. Acetylcholinesterase inhibitors (increase availability of acetylcholine at the neuromuscular junction). Pyridostigmine (first-line symptomatic therapy) Dose: 30–60 mg orally every 4–6 hours (adjust per response) Improves muscle strength and fatigability Neostigmine (less commonly used, short-acting).

**2. Immunosuppressive Therapy:** Used to reduce autoantibody production and disease activity Corticosteroids (prednisone) – first-line immunosuppressant Steroid-sparing agents: Azathioprine Mycophenolate mofetil Cyclosporine Goal: minimize long-term steroid side effects while maintaining disease control.

**3. Rapid Immunomodulatory Therapy (for crisis or severe exacerbation) Plasmapheresis (plasma exchange):** removes circulating autoantibodies Intravenous immunoglobulin (IVIG): neutralizes pathogenic antibodies Used in myasthenic crisis or preoperatively before thymectomy.

**4. Surgical Management:** Thymectomy – indicated in Thymoma-associated MG Generalized MG (especially early-onset) Can improve symptoms and may induce remission.

**5. Supportive Care:** Respiratory support for patients with respiratory muscle weakness Physical therapy to maintain mobility and prevent deconditioning Patient education on avoiding drugs that exacerbate MG (e.g., aminoglycosides, beta-blockers).

**6. Lifestyle and Monitoring:** Avoid excessive fatigue and infections, which may precipitate weakness Regular follow-up for adjusting medications and monitoring side effects Vaccinations and stress management as preventive strategies.

### Complications

Myasthenia gravis (MG), if inadequately treated or poorly controlled, can lead to several acute and chronic complications affecting muscle function, respiratory status, and overall quality of life.

**1. Myasthenic Crisis:** Life-threatening complication due to severe weakness of respiratory muscles Requires mechanical ventilation and intensive care Can be triggered by infections, surgery, stress, or medications.

**2. Respiratory Complications:** Hypoventilation leading to respiratory failure Recurrent respiratory infections due to weak cough and ineffective airway clearance.

**3. Bulbar Complications:** Dysphagia → risk of aspiration pneumonia Dysarthria and difficulty in swallowing affect nutrition and communication.

**4. Medication-Related Complications Adverse effects of long-term immunosuppressive therapy:** Corticosteroids → osteoporosis, diabetes, hypertension, infections Azathioprine / Mycophenolate → bone marrow suppression, liver toxicity Cholinesterase inhibitors → diarrhea, abdominal cramps, muscle cramps.

**5. Thymectomy-Related Complications:** Surgical risks bleeding, infection, respiratory complications Postoperative transient worsening of MG symptoms in some patients.

**6. Psychosocial Complications:** Chronic fatigue, functional limitations Depression, anxiety, and reduced quality of life due to persistent weakness.

### Lifestyle Modifications

Lifestyle modifications are an important adjunct to pharmacological and surgical management of myasthenia gravis (MG). They help reduce symptom exacerbations, improve daily functioning, and enhance quality of life.

**1. Activity and Rest Management:** Balance activity and rest: Avoid prolonged or strenuous activity that may worsen muscle fatigue Pacing of daily tasks: Break activities into shorter periods with rest intervals Energy conservation techniques: Use adaptive tools to reduce physical strain.

**2. Diet and Nutrition:** Soft, easily chewable foods if bulbar muscles are weak Small, frequent meals to prevent fatigue during eating Adequate hydration to maintain overall health and prevent complications.

**3. Infection Prevention:** Vaccinations (influenza, pneumococcal) as recommended Prompt treatment of infections to prevent exacerbation good hand hygiene and avoiding sick contacts.

**4. Temperature and Environmental Control:** Avoid exposure to extreme heat, which may worsen muscle weakness Maintain a comfortable, stress-free environment.

**5. Medication Awareness:** Avoid drugs that can exacerbate MG, including: Aminoglycosides Beta-blockers Magnesium-containing drugs Regularly review medications with healthcare providers.

**6. Stress Management:** Practice relaxation techniques (yoga, meditation, deep breathing) Adequate sleep and rest to reduce fatigue and improve immune function.

**7. Regular Follow-Up and Monitoring:** Routine check-ups with neurologist Monitoring for disease progression or medication side effects Adjustment of therapy based on activity levels and symptoms.

### CONCLUSION

Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disorder characterized by fluctuating muscle weakness and fatigability, which can significantly impact daily functioning and quality of life. The disease arises from autoantibody-mediated impairment of neuromuscular transmission, often associated with thymic abnormalities and genetic susceptibility. Clinical presentation varies from purely ocular symptoms to generalized muscle involvement, including bulbar and respiratory muscles. Diagnosis relies on a combination of clinical evaluation, antibody testing, electrophysiological studies, and thymic imaging, allowing for early and accurate identification of the disease. Management is multimodal, including acetylcholinesterase inhibitors, immunosuppressive therapy, rapid immunomodulation during crises,

thymectomy when indicated, and supportive care. Lifestyle modifications, patient education, and close monitoring are essential to prevent exacerbations and improve outcomes. With timely diagnosis, individualized treatment, and comprehensive care, patients with myasthenia gravis can achieve significant symptom control, improved functional capacity, and enhanced quality of life. Ongoing research and advances in immunotherapy continue to provide promising strategies for better disease management and long-term prognosis.

### REFERENCES

- Dresser L, Wlodarski R, Rezaia K, Soliven B. Myasthenia Gravis: Epidemiology, Pathophysiology and Clinical Manifestations. *J Clin Med.* 2021; 10(11): 2235. Review providing a comprehensive overview of MG, including disease spectrum and mechanisms.
- Statland JM, Ciafaloni E. Myasthenia gravis: Five new things. *Neurol Clin Pract.* 2013; 3(2): 126–133. A concise clinical review highlighting key clinical aspects.
- PubMed Gilhus NE, Skeie G, Romi F, et al. Myasthenia gravis — autoantibody characteristics and their implications for therapy. *Nat Rev Neurol.* 2016; 12: 259–268. Authoritative review on autoantibodies and therapeutic implications.
- Grob D, Brunner N, Namba T, Pagala M. Lifetime course of myasthenia gravis. *Muscle Nerve.* 2008; 37(2): 141–149. Classic article on natural history and longitudinal disease course. PubMed.
- Hehir MK, Silvestri NJ. Generalized myasthenia gravis: classification, clinical presentation, natural history, and epidemiology. *Neurol Clin.* 2018; 36: 253–260. Comprehensive clinical review.
- Rousseff RT. Diagnosis of Myasthenia Gravis. *J Clin Med.* 2021; 10(8): 1736. Review focusing on diagnostic methods and challenges.
- Grob D, Brunner N, Namba T, Pagala M. Myasthenia gravis: review of pathogenesis, clinical features and treatment. *Curr Opin Neurol.* 2007; 18(1): 15–23. Earlier but foundational review of MG pathogenesis and management.
- ScienceDirect Grob D, Brunner N, Namba T, Pagala M. Myasthenia Gravis: A Review of Pathogenesis and Treatment. *JAMA Intern Med.* (Classic review on MG disease process and therapy.) JAMA Network Mishra AK, Varma A. Myasthenia Gravis: A Systematic Review. *Cureus.* 2023. Provides updated evidence on clinical features and management.
- Global prevalence and treatment systematic review.
- Mishra AK, Varma A. Myasthenia Gravis: A Systematic Review. *Cureus.* 2023; 15(12): e50017.  PMC.
- Gilhus NE, Skeie G, Romi F, et al. Myasthenia gravis — autoantibody characteristics and their implications for therapy. *Nat Rev Neurol.* 2016; 12: 259–268.

12. Gilhus NE, Tzartos S, Evoli A, et al. Myasthenia gravis. *Nat Rev Dis Primers*. 2019; 5: 30.
13. Dresser L, Wlodarski R, Rezaia K, Soliven B. Myasthenia Gravis: Epidemiology, Pathophysiology and Clinical Manifestations. *J Clin Med*. 2021; 10(11): 2235. [irjponline.org](https://www.irjponline.org)
14. Evoli A, Gilhus NE, Guptill J. News and Views in the Management of Myasthenia Gravis. *Front Neurol*. 2021; 12: 769086. [frontiersin.org](https://www.frontiersin.org).
15. Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms. *PubMed*. 2014; (detailed immunological mechanisms, thymus involvement). *PubMed*.
16. StatPearls Authors. Myasthenia Gravis. *StatPearls [Internet]*. Updated 2025; covers epidemiology and antibody subtypes in MG. *NCBI*
17. Myasthenia gravis — pathogenesis, diagnosis, and therapy. *PubMed review*. *PubMed*
18. Torpy JM, Glass TM, Glass RM. Myasthenia Gravis. *JAMA Patient Page*.
19. JAMA Network Myasthenia gravis: pathophysiology, diagnosis, and treatment. *PubMed review*. *PubMed*
20. Myasthenia Gravis: diagnosis and treatment. (Older but useful clinical review).
21. *Indian Journal of Ophthalmology*. Ocular myasthenia gravis: a review. (Focused on ocular manifestations). *Lippincott Journals*
22. Grob D. Myasthenia Gravis: A Review of Pathogenesis and Treatment. *JAMA Intern Med*. (Classic foundational article). *JAMA Network*
23. (Historical review) Myasthenia Gravis: An Illustrated History. *JAMA Network*.